Patent ID: 8465744

Claim:
A method for the treatment of inflammation mediated by IL-1β or associated with an increased level of IL-1β comprising administering to a patient suffering from such inflammation a pharmaceutically effective amount of a pharmaceutical composition, said composition comprising a neutralising antibody having specificity for human IL-1β, the antibody comprising a heavy chain and a light chain, wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:5 for CDR-H1, the sequence given in SEQ ID NO:6 for CDR-H2 and the sequence given in SEQ ID NO:7 for CDR-H3 and wherein the variable domain of the light chain comprises the sequence given in SEQ ID NO:8 for CDR-L1, the sequence given in SEQ ID NO:9 for CDR-L2 and the sequence given in SEQ ID NO:10 for CDR-L3, in combination with one or more of a pharmaceutically acceptable excipient, diluent or carrier.